Cargando…

Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry

BACKGROUND: Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. METHODS: Proteomic analysis of the human...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dandan, Wu, Jie, Liu, Zhongjuan, Qiu, Ling, Zhang, Yimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346861/
https://www.ncbi.nlm.nih.gov/pubmed/32704452
http://dx.doi.org/10.7717/peerj.9507
_version_ 1783556480703660032
author Li, Dandan
Wu, Jie
Liu, Zhongjuan
Qiu, Ling
Zhang, Yimin
author_facet Li, Dandan
Wu, Jie
Liu, Zhongjuan
Qiu, Ling
Zhang, Yimin
author_sort Li, Dandan
collection PubMed
description BACKGROUND: Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. METHODS: Proteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). In addition, 15 patients with benign thyroid nodules (TNs) and 10 healthy controls (HCs) were included in this study. Subsequently, 17 differentially expressed proteins were identified in 291 patients with TC, including 247 with PTC, 38 with MTC, and six with FTC, and 69 patients with benign TNs and 176 with HC, using enzyme-linked immunosorbent assays. RESULTS: In total, 517 proteins were detected in the serum samples using an Orbitrap Q-Exactive-plus mass spectrometer. The amyloid beta A4 protein, apolipoprotein A-IV, gelsolin, contactin-1, gamma-glutamyl hydrolase, and complement factor H-related protein 1 (CFHR1) were selected for further analysis. The median serum CFHR1 levels were significantly higher in the MTC and FTC groups than in the PTC and control groups (P < 0.001). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL. CONCLUSION: CFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity.
format Online
Article
Text
id pubmed-7346861
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-73468612020-07-22 Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry Li, Dandan Wu, Jie Liu, Zhongjuan Qiu, Ling Zhang, Yimin PeerJ Bioinformatics BACKGROUND: Distinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC. METHODS: Proteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). In addition, 15 patients with benign thyroid nodules (TNs) and 10 healthy controls (HCs) were included in this study. Subsequently, 17 differentially expressed proteins were identified in 291 patients with TC, including 247 with PTC, 38 with MTC, and six with FTC, and 69 patients with benign TNs and 176 with HC, using enzyme-linked immunosorbent assays. RESULTS: In total, 517 proteins were detected in the serum samples using an Orbitrap Q-Exactive-plus mass spectrometer. The amyloid beta A4 protein, apolipoprotein A-IV, gelsolin, contactin-1, gamma-glutamyl hydrolase, and complement factor H-related protein 1 (CFHR1) were selected for further analysis. The median serum CFHR1 levels were significantly higher in the MTC and FTC groups than in the PTC and control groups (P < 0.001). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL. CONCLUSION: CFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity. PeerJ Inc. 2020-07-06 /pmc/articles/PMC7346861/ /pubmed/32704452 http://dx.doi.org/10.7717/peerj.9507 Text en © 2020 Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Bioinformatics
Li, Dandan
Wu, Jie
Liu, Zhongjuan
Qiu, Ling
Zhang, Yimin
Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
title Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
title_full Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
title_fullStr Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
title_full_unstemmed Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
title_short Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
title_sort novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
topic Bioinformatics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346861/
https://www.ncbi.nlm.nih.gov/pubmed/32704452
http://dx.doi.org/10.7717/peerj.9507
work_keys_str_mv AT lidandan novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry
AT wujie novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry
AT liuzhongjuan novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry
AT qiuling novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry
AT zhangyimin novelcirculatingproteinbiomarkersforthyroidcancerdeterminedthroughdataindependentacquisitionmassspectrometry